Triazole compounds and the use thereof

The invention relates to triazole compounds and to the use of such compounds. Said compounds have valuable therapeutic properties and can be used to treat disorders which respond to dopamine D.sub.3 receptor ligands.
Compounds which are of the type under discussion here and have physiological activity have been disclosed. U.S. Pat. Nos. 4,338,453, 4,408,049 and 4,577,020 describe triazole compounds which have antiallergic activity.
Neurons receive their information inter alia via G protein-coupled receptors. There are numerous substances which exert their effect via these receptors. One of them is dopamine.
Confirmed findings on the presence of dopamine and its physiological function as neurotransmitter have been published. Cells which respond to dopamine are connected with the etiology of schizophrenia and Parkinson's disease. These and other disorders are treated with drugs which interact with dopamine receptors.
By 1990, two subtypes of dopamine receptors had been clearly defined pharmacologically, namely D.sub.1 and D.sub.2 receptors.
Sokoloff et al., Nature 1990, 347: 146-151, found a third subtype, namely D.sub.3 receptors. They are expressed mainly in the limbic system. The D.sub.3 receptors differ structurally from the D.sub.1 and D.sub.2 receptors in about half the amino-acid residues.
The effect of neuroleptics has generally been ascribed to their affinity for D.sub.2 receptors. Recent receptor-binding studies have confirmed this. According to these, most dopamine antagonists, like neuroleptics, have high affinity for D.sub.2 receptors but only low affinity for D.sub.3 receptors.
We have now found, surprisingly, that the compounds according to the invention have a high affinity for the dopamine D.sub.3 receptor and only a low affinity for the D.sub.2 receptor. They are thus selective D.sub.3 ligands.
The present invention therefore relates to triazole compounds of the formula I: ##STR1## where A is a straight-chain or branched C.sub.1 -C.sub.18 -alkylene group which may comprise at least one group selected from O, S, NR.sup.3, CONR.sup.3, NR.sup.3 CO, COO, OCO, C.sub.3 -C.sub.6 -cycloalkylene or a double or triple bond, X is a radical of the formula: ##STR2## R.sup.1 is H, CO.sub.2 R.sup.3, NR.sup.3 R.sup.4, OR.sup.4, C.sub.3 -C.sub.6 -cycloalkyl or C.sub.1 -C.sub.8 -alkyl which is unsubstituted or substituted by OH, OC.sub.1 -C.sub.8 -alkyl or halogen;
R.sup.2 has the meanings indicated for R.sup.1 or is CF.sub.3, SR.sup.3, halogen or CN;
R.sup.3 is H or C.sub.1 -C.sub.8 -alkyl which is unsubstituted or substituted by OH, OC.sub.1 -C.sub.8 -alkyl, phenyl or halogen;
R.sup.4 has the meanings indicated for R.sup.3 or is COR.sup.3 or CO.sub.2 R.sup.3 ;
Ar is phenyl, pyridyl, pyrimidyl or triazinyl, where Ar may have from one to four substituents which are selected, independently of one another, from OR.sup.4, C.sub.1 -C.sub.8 -alkyl, C.sub.2 -C.sub.6 -alkenyl, C.sub.2 -C.sub.6 -alkynyl, halogen, CN, CO.sub.2 R.sup.3, NO.sub.2, SO.sub.2 R.sup.3, SO.sub.3 R.sup.3, NR.sup.3 R.sup.4, SO.sub.2 NR.sup.3 R.sup.4, SR.sup.3, CF.sub.3, CHF.sub.2, a 5- or 6-membered carbocyclic aromatic or nonaromatic ring and a 5- or 6-membered heterocyclic aromatic or nonaromatic ring having 1 to 4 hetero atoms selected from O, S and N, where the carbocyclic or heterocyclic ring may be unsubstituted or substituted by C.sub.1 -C.sub.8 -alkyl, halogen, OC.sub.1 -C.sub.8 -alkyl, OH, NO.sub.2 or CF.sub.3 and where Ar may also be fused to a carbocyclic or heterocyclic ring of the type defined above, and the salts thereof with physiologically tolerated acids.
The compounds according to the invention are selective dopamine D.sub.3 receptor ligands which intervene regioselectively in the limbic system and, because of their low affinity for the D.sub.2 receptor, have fewer side effects than classical neuroleptics, which are D.sub.2 receptor antagonists. The compounds can therefore be used to treat disorders which respond to dopamine D.sub.3 receptor antagonists or agonists, eg. for treating disorders of the central nervous system, in particular schizophrenia, depression, neuroses and psychoses. They can additionally be used to treat sleep disorders and nausea and as antihistamines.
Within the scope of the present invention, the following terms have the meanings indicated below:
Alkyl (also in radicals such as alkoxy, alkyl-amino etc.) means a straight-chain or branched alkyl group having 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms and, in particular, 1 to 4 carbon atoms. The alkyl group can have one or more substituents which are selected, independently of one another, from OH and OC.sub.1 -C.sub.8 -alkyl.
Examples of an alkyl group are methyl, ethyl, n-propyl, i-propyl, n-butyl, isobutyl, t-butyl etc.
Alkylene stands for straight-chain or branched radicals having, preferably, 2 to 15 carbon atoms, particularly preferably 3 to 10 carbon atoms.
The alkylene groups may comprise at least one of the abovementioned groups. This can--just like the double or triple bond mentioned--be arranged in the alkylene chain at any point or at the end of the chain so that it connects the chain to the triazole residue. The latter is preferred. When the alkylene group comprises a double or triple bond, it has at least three carbon atoms in the chain.
Halogen is F, Cl, Br, I and, in particular, Cl, Br, I.
R.sup.1 and R.sup.2 are preferably, independently of one another, H, C.sub.1 -C.sub.8 -alkyl, NR.sup.3 R.sup.4 or OR.sup.4.
Ar can have one, two, three or four substituents. They are preferably selected, independently of one another, from halogen, CF.sub.3, CHF.sub.2, NR.sup.3 R.sup.4, OR.sup.4, NO.sub.2, C.sub.1 -C.sub.8 -alkyl, OC.sub.1 -C.sub.8 -alkyl, SR.sup.3 and CN, where R.sup.3 and R.sup.4 have the abovementioned meanings.
If one of the substituents of Ar is C.sub.1 -C.sub.8 -alkyl, a branched radical, in particular the isopropyl or t-butyl group, is preferred.
Ar preferably has at least one substituent and is, in particular, ##STR3## where D.sup.1, D.sup.2 and D.sup.3 are, independently of one another, CR or N, and R, X and Y are H or are the substituents of the radical Ar indicated above or below.
Ar is preferably unsubstituted or substituted phenyl, 2-, 3- or 4-pyridinyl or 2-, 4(6)- or 5-pyrimidyl.
When one of the substituents of the radical Ar is a 5- or 6-membered heterocyclic ring, examples thereof are a pyrrolidine, piperidine, morpholine, piperazine, pyridine, pyrimidine, triazine, pyrrole, thiophene, thiazole, imidazole, oxazole, isoxazole, pyrazole or thiadiazole residue.
When one of the substituents of the radical Ar is a carbocyclic radical, it is, in particular, a phenyl, cyclopentyl or cyclohexyl radical.
When Ar is fused to a carbocyclic or heterocyclic radical, Ar is, in particular, a naphthalene, di- or tetrahydronaphthalene, quinoline, di- or tetrahydroquinoline, indole, dihydroindole, benzimidazole, benzothiazole, benzothiadiazole, benzopyrrole or benzotriazole residue.
X is preferably ##STR4##
A preferred embodiment comprises compounds of the formula I where A is C.sub.3 -C.sub.10 -alkylene which comprises at least one group which is selected from O, S, NR.sup.3, cyclohexylene, in particular 1,4-cyclohexylene, and a double or triple bond, where R.sup.3 is as defined above.
Another preferred embodiment comprises compounds of the formula I where
R.sup.1 is H, OR.sup.4 where R.sup.4 is H or C.sub.1 -C.sub.8 -alkyl, or C.sub.3 -C.sub.6 -cycloalkyl or C.sub.1 -C.sub.8 -alkyl which is unsubstituted or substituted by OH, OC.sub.1 -C.sub.8 -alkyl or halogen;
R.sup.2 is H, C.sub.1 -C.sub.8 -alkyl which is unsubstituted or substituted by OH, OC.sub.1 -C.sub.8 -alkyl or halogen, or NR.sup.3 R.sup.4 where R.sup.3 and R.sup.4 are, independently of one another, H, phenyl-C.sub.1 -C.sub.8 -alkyl or C.sub.1 -C.sub.8 -alkyl, or OR.sup.4 where R.sup.4 is H or C.sub.1 -C.sub.8 -alkyl, or CF.sub.3 ;
A is as defined in claim 3, and
Ar is phenyl, pyridyl or pyrimidyl which may have one, two, three or four substituents which are selected from H, C.sub.1 -C.sub.8 -alkyl which is unsubstituted or substituted by OH, OC.sub.1 -C.sub.8 -alkyl or halogen, or OR.sup.4 where R.sup.4 is H, C.sub.1 -C.sub.8 -alkyl which is unsubstituted or substituted by OH, OC.sub.1 -C.sub.8 -alkyl or halogen, or CHF.sub.2, CF.sub.3, CN, Halogen, C.sub.2 -C.sub.6 -alkenyl, C.sub.2 -C.sub.6 -alkynyl, phenyl, naphthyl and a 5- or 6-membered heterocyclic aromatic radical with 1 to 3 hetero atoms selected from O, N and S.
Another preferred embodiment comprises compounds of the formula I where
R.sup.1 is H or C.sub.1 -C.sub.8 -alkyl which is unsubstituted or substituted by OH, OC.sub.1 -C.sub.8 -alkyl or halogen;
R.sup.2 is H, C.sub.1 -C.sub.8 -alkyl which is unsubstituted or substituted by OH, OC.sub.1 -C.sub.8 -alkyl or halogen, or NR.sup.3 R.sup.4 where R.sup.3 and R.sup.4 are, independently of one another, H or C.sub.1 -C.sub.8 -alkyl, or OR.sup.4 where R.sup.4 is H or C.sub.1 -C.sub.8 -alkyl, or CF.sub.3 ;
A is C.sub.1 -C.sub.10 -alkylene which may comprise an oxygen or sulfur atom or the group NR.sup.3 where R.sup.3 is as defined above;
Ar is phenyl which may have one to four substituents which are selected, independently of one another, from H, CN, SR.sup.3, halogen, C.sub.1 -C.sub.8 -alkyl which is unsubstituted or substituted by OH, OC.sub.1 -C.sub.8 -alkyl or halogen, or phenyl, naphthyl, OR.sup.4, NO.sub.2, NR.sup.3 R.sup.4, CHF.sub.2 and CF.sub.3, where R.sup.3 and R.sup.4 have the stated meanings.
Particularly preferred in this connection are the compounds of the formula I where
A is SC.sub.3 -C.sub.10 -alkylene, OC.sub.3 -C.sub.10 -alkylene or NR.sup.3 -C.sub.3 -C.sub.10 -alkylene, where R.sup.3 is H or C.sub.1 -C.sub.8 -alkyl,
R.sup.1 is H or C.sub.1 -C.sub.8 -alkyl;
R.sup.2 has the abovementioned meanings;
X is: ##STR5## Ar is phenyl which has one to four substituents which are, independently of one another, H, C.sub.1 -C.sub.8 -alkyl, OC.sub.1 -C.sub.8 -alkyl, CHF.sub.2, CF.sub.3 or CN.
Ar has, in particular, two substituents which are located in positions 3 and 5, with one substituent being CF.sub.3, CHF.sub.2 or C.sub.1 -C.sub.8 -alkyl and the other substituent being H or C.sub.1 -C.sub.8 -alkyl.
Another preferred embodiment comprises compounds of the formula I where
Ar is pyrimidinyl which has one to three substituents which are selected, independently of one another, from H, C.sub.1 -C.sub.8 -alkyl, phenyl, naphthyl, C.sub.3 -C.sub.6 -cyclohexyl, OH, OC.sub.1 -C.sub.8 -alkyl, halogen, CN, CF.sub.3, CHF.sub.2 and a 5- or 6-membered heterocyclic aromatic radical with 1 to 3 hetero atoms selected from O, N and S;
R.sup.1 is H or C.sub.1 -C.sub.8 -alkyl which is unsubstituted or substituted by OH, OC.sub.1 -C.sub.8 -alkyl or halogen,
R.sup.2 is H, NR.sup.3 R.sup.4 or OR.sup.4 where R.sup.3 and R.sup.4 are, independently of one another, H, C.sub.1 -C.sub.8 -alkyl or phenyl-C.sub.1 -C.sub.8 -alkyl;
A is C.sub.1 -C.sub.10 -alkylene which may comprise at least one group selected from O, S, NR.sup.3 where R.sup.3 is H or C.sub.1 -C.sub.8 -alkyl, and a double or triple bond; and
X is as defined above.
Another preferred embodiment comprises compounds of the formula I where
Ar is pyridinyl which has one to four substituents which are selected, independently of one another, from H, C.sub.1 -C.sub.8 -alkyl, phenyl, naphthyl, OH, OC.sub.1 -C.sub.8 -alkyl, halogen, CF.sub.3, CN, C.sub.2 -C.sub.6 -alkenyl, C.sub.2 -C.sub.6 -alkynyl and a 5- or 6-membered heterocyclic aromatic radical with 1 to 3 hetero atoms selected from O, N and S;
R.sup.1 is H, C.sub.1 -C.sub.8 -alkyl, C.sub.3 -C.sub.6 -cycloalkyl or OR.sup.4 where R.sup.4 is H or C.sub.1 -C.sub.8 -alkyl which is unsubstituted or substituted by OH, OC.sub.1 -C.sub.8 -alkyl or halogen; and
R.sup.2, A and X are as defined above.
The invention also embraces the acid addition salts of the compounds of the formula I with physiologically tolerated acids. Examples of suitable physiologically tolerated organic and inorganic acids are hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, oxalic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, adipic acid or benzoic acid. Other acids which can be used are described in Fortschritte der Arzneimittelforschung, Volume 10, pages 224 et seq., Birkhauser Verlag, Basle and Stuttgart, 1966.
The compounds of the formula I may have one or more centers of asymmetry. The invention therefore includes not only the racemates but also the relevant enantiomers and diastereomers. The invention also includes the tautomeric forms in each case.
The compounds of the formula I can be prepared by methods similar to conventional ones as described, for example, in Houben Weyl "Handbuch der Organishen Chemie", 4th Ed., Thieme Verlag, Stuttgart 1994, Volume E8/d, pages 479 et seq.; and A. R. Katritzky, C. W. Rees (ed.) "Comprehensive Heterocyclic Chemistry", 1st Ed. Pergamon Press 1984, in particular Vol. 5, part 4a, pages 733 et seq. and literature cited therein. The proess for preparing the compounds comprises i) reacting a compound of the general formula II: ##STR6## where Y.sup.1 is a conventional leaving group, with a compound of the formula III
H--X--Ar;
ii) to prepare a compound of the formula I where A is an oxygen or sulfur atom or NR.sup.3 :
a) reacting a compound of the formula IV: ##STR7## where Z.sup.1 is O, S or NR.sup.3 and A.sup.1 is C.sub.0 -C.sub.18 -alkylene, with a compound of the formula VI
Y.sup.1 --A.sup.2 --X--Ar
where Y.sup.1 has the abovementioned meanings, and A.sup.2 is C.sub.1 -C.sub.18 -alkylene, where A.sup.1 and A.sup.2 together have 1 to 18 carbon atoms;
iii) to prepare a compound of the formula I where A comprises the group COO or CONR.sup.3 :
a) reacting a compound of the formula VII: ##STR8## where Y.sup.2 is OH, OC.sub.1 -C.sub.4 -alkyl, Cl or, together with CO, is an activated carboxyl group, and A.sup.1 has the abovementioned meanings, with a compound of the formula VIII:
Z.sup.1 --A.sup.2 --X--Ar
where A.sup.2 has the abovementioned meanings, and Z.sup.1 is OH or NHR.sup.3,
iv) to prepare a compound of the formula I where A comprises the group OCO or NR.sup.3 CO:
a) reacting a compound of the formula IV ##STR9## where Z.sup.1 is O or NR.sup.3, with a compound of the formula X:
Y.sup.2 CO--A.sup.2 --X--Ar
where B and Y.sup.2 have the abovementioned meanings, and where R.sup.1, R.sup.2, A, B and Ar have the abovementioned meanings.
The reactions described above generally take place in a solvent at from room temperature to the boiling point of the solvent used. Examples of solvents which can be used are ethyl acetate, tetrahydrofuran, dimethylformamide, dimethoxyethane, toluene, xylene or a ketone, such as acetone or methyl ethyl ketone.
An acid acceptor is present if required. Suitable acid acceptors are inorganic bases such as sodium or potassium carbonate, sodium methoxide, sodium ethoxide, sodium hydride or organic bases such as triethylamine or pyridine. The latter may also serve as solvents.
The crude product is isolated in a conventional way, for example by filtration, removal of the solvent by distillation or extraction from the reaction mixture. The resulting compound can be purified in a conventional way, for example by recrystallization from a solvent, chromatography or conversion into an acid addition compound.
The acid addition salts are prepared in a conventional way by mixing the free base with the appropriate acid, possibly in solution in an organic solvent, for example a lower alcohol such as methanol, ethanol or propanol, an ether such as methyl t-butyl ether, a ketone such as acetone or methyl ethyl ketone, or an ester such as ethyl acetate.
The abovementioned starting materials are disclosed in the literature or can be prepared by known processes.
To treat the abovementioned disorders, the compounds according to the invention are administered in a conventional manner orally or parenterally (subcutaneously, intravenously, intramuscularly, intraperitoneally). Administration can also take place with vapors or sprays through the nasopharyngeal space.
The dosage depends on the age, condition and weight of the patient and on the mode of administration. As a rule, the daily dose of active substance is about 10 to 1000 mg per patient and day on oral administration and about 1 to 500 mg per patient and day on parenteral administration.
The invention also relates to pharmaceutical compositions which contain the compounds according to the invention. These compositions are in the usual solid or liquid pharmaceutical administration forms, for example as tablets, film-coated tablets, capsules, powders, granules, sugar-coated tablets, suppositories, solutions or sprays. The active substances can in these cases be processed with conventional pharmaceutical aids such as tablet binders, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, release-slowing agents, antioxidants and/or propellant gases (cf. H. Sucker et al., Pharmazeutische Technologie, Thieme-Verlag, Stuttgart, 1978). The administration forms obtained in this way normally contain the active substance in an amount from 1 to 99% by weight.
The following examples serve to explain the invention without limiting it.

EXAMPLE 1
4-Methyl-3-[3-(4-{3-trifluoromethylphenyl}piperazinyl)propylmercapto]-4H-1,2,4-triazole ##STR10## a) 1-(3-Chloropropyl)-4-(3-trifluoromethylphenyl)piperazine
30 g (0.13 mol) of m-trifluoromethylphenylpiperazine, 23 g (0.146 mol) of 1,3-bromochloropropane [sic] and 15 g (0.148 mol) of triethylamine in 200 ml of THF were refluxed for 4 hours. Cooling was followed by filtration with suction and concentration. The viscous residue was taken up in ethyl acetate, washed with water, dried over MgSO.sub.4 and then concentrated. The resulting residue comprised 39 g of product as yellowish oil (quantitative yield).
b) 4-Methyl-3-[3-(4-{3-trifluoromethylphenyl}piperazinyl)propylmercapto]-4H-1,2,4-triazole
1.15 g (10 mmol) of 3-mercapto-4-methyl-4H-1,2,4-triazole, 3.1 g (10.1 mmol) of 1-(3-chloropropyl)-4-(3-trifluoromethylphenyl)piperazine and 1.5 g (15 mmol) of triethylamine in 5 ml of DMF were stirred at 100.degree. C. for 1 hour. The mixture was then poured into 5% strength hydrochloric acid and extracted with ethyl acetate. The aqueous phase was made alkaline with sodium hydroxide solution and then extracted again with ethyl acetate, and the organic phase was dried over MgSO.sub.4 and concentrated. The residue was purified by chromatography (mobile phase: CH.sub.2 Cl.sub.2 /CH.sub.3 OH=95/5). 2.1 g of product were obtained as a yellowish oil (=55% yield).
H-NMR [.delta., ppm]: 2.02 (2H); 2.55 (2H); 2.61 (4H); 3.23 (6H); 3.33 (2H); 3.61 (3H); 7.06 (3H); 7.33 (1H); 8.12 (1H).
EXAMPLE 2
4-Methyl-3-[5-(4-{3-trifluoromethylphenyl}piperazinyl)-pentylmercapto]-4H-1,2,4-triazole ##STR11## a) 3-(5-Chloropentylmercapto)-4-methyl-4H-1,2,4-triazole
2.88 g (25 mmol) of 3-mercapto-4-methyl-4H-1,2,4-triazole, 4.64 g (25 mmol) of 1,5-bromochloropentane [sic] and 5.58 g (25.5 mmol) of triethylamine in 100 ml of THF were refluxed for 4 hours. Cooling was followed by filtration with suction, concentration and purification of the residue by chromatography (mobile phase: CH.sub.2 Cl.sub.2 /CH.sub.3 OH=95/5). 1.9 g of product were obtained (=35% yield).
b) 4-Methyl-3-[5-(4-{3-trifluoromethylphenyl}piperazinyl)pentylmercapto]-4H-1,2,4-triazole
1.9 g (8.66 mmol) of product from 2a), 2.19 g (9.52 mmol) of m-trifluoromethylphenylpiperazine and 0.96 g (9.52 mmol) of triethylamine in 5 ml of DMF were stirred at 90.degree. C. for 5 hours. The mixture was then poured into water and extracted three times with CH.sub.2 Cl.sub.2, and the organic phase was dried over MgSO.sub.4 and concentrated. The residue was mixed with methyl t-butyl ether and filtered with suction, and the mother liquor was concentrated. Purification by chromatography (mobile phase: CH.sub.2 Cl.sub.2 /CH.sub.3 OH=95/5) resulted in 2.1 g of product (=59% yield).
Melting point 70-76.degree. C.
The following compounds were prepared in a similar way:
__________________________________________________________________________ Physical data, H-NMR [.delta., ppm]No. Example melting point [.degree. C.]__________________________________________________________________________ ##STR12## 1.83(2H); 2.45(6H); 3.0(2H); 3.27(4H); 6.0(2H); 7.05(1H); 7.15(1H); 7.2(1H); 7.4(1H); 11.95(1H)4 ##STR13## 1.85(2H); 2.3(3H); 2.45(2H); 2.5(4H); 3.1(2H); 3.2(4H); 5.8(2H); 7.05(1H); 7.15(1H); 7.2(1H); 7.4(1H)5 ##STR14## 2.1(2H); 2.7(6H); 3.22(2H); 3.42(4H); 7.1(3H); 7.38(1H); 7.92(1H)6 ##STR15## 200-2057 ##STR16## 2.05(2H); 2.55(2H); 2.6(4H); 3.23(4H); 3.4(2H); 3.65(3H); 7.08(3H); 7.35(1H)8 ##STR17## 2.0(2H); 2.53(2H); 2.6(4H); 3.13(2H); 3.25(7H); 7.08(3H); 7.35(1H); 9.88(1H)9 ##STR18## 1.5(6H); 1.98(2H); 2.55(2H); 2.62(4H); 3.15(2H); 3.22(4H); 4.32(1H); 7.08(3H); 7.35(1H); 10.0(1H)10 ##STR19## 1.95(2H); 2.5(2H); 2.58(4H); 3.1(2H); 3.22(4H); 3.4(3H); 4.4(2H); 7.08(3H); 7.35(1H)11 ##STR20## 2.52(4H); 3.0(2H); 3.22(4H); 3.4(3H); 3.64(2H); 4.96(2H); 5.62(1H); 5.72(1H); 7.05(3H); 7.3(1H)12 ##STR21## 1.95(2H); 2.52(2H); 2.6(4H); 3.12(2H); 3.22(4H); 3.4(3H); 4.2(2H); 6.6(1H); 7.0(3H); 7.35(1H)13 ##STR22## 1.15(6H); 1.75(2H); 2.45(10H); 2.9(2H); 3.08(4H); 3.3(3H); 5.95(2H); 6.45(1H); 6.55(2H)14 ##STR23## 166-17115 ##STR24## 1.25(18H); 1,75 (2H); 2.4(2H); 2.45(4H); 2.9(2H); 3.1(4H); 3.35(3H); 5.95(2H); 6.75(2H); 6.88(1H)__________________________________________________________________________
The compounds according to the invention which compiled in Tables 1 to 3 below were obtained in a similar manner.
The compounds compiled in Tables 4 to 8 below can likewise be obtained in a similar manner.
TABLE 1__________________________________________________________________________ ##STR25##Example No. R.sup.1 R.sup.2 R.sup.6 X-Y A.sub.1 A.sub.2__________________________________________________________________________16 CH.sub.3 NH.sub.2 i Prop CH.sub.2 --N S --(CH.sub.2).sub.3 --17 CH.sub.3 NH.sub.2 CF.sub.3 CH.sub.2 --N S --(CH.sub.2).sub.2 CH.dbd.CH(CH.sub.2).sub.2 --18 CH.sub.3 NH.sub.2 CF.sub.3 CH.sub.2 --N S --(CH.sub.2).sub.2 --19 CH.sub.3 NH.sub.2 CF.sub.3 CH.sub.2 --N S --CH.sub.2 C(CH.sub.3).dbd.CHCH.sub.2 --20 CH.sub.3 CH.sub.2 NH.sub.2 CF.sub.3 CH.sub.2 --N S --(CH.sub.2).sub.3 --21 CH.sub.3 NH.sub.2 CF.sub.3 CH.sub.2 --N S ##STR26##22 n Prop NH.sub.2 CF.sub.3 CH.sub.2 --N S --(CH.sub.2).sub.3 --23 i Prop NH.sub.2 CF.sub.3 CH.sub.2 --N S --(CH.sub.2).sub.3 --24 CH.sub.3 CH.sub.2 NH.sub.2 CHF.sub.2 CH.sub.2 --N S --(CH.sub.2).sub.3 --25 n Prop NH.sub.2 CHF.sub.2 CH.sub.2 --N S --(CH.sub.2).sub.3 --26 CH.sub.3 CH.sub.2 NH.sub.2 i Prop CH.sub.2 --N S --(CH.sub.2).sub.3 --27 n Prop NH.sub.2 i Prop CH.sub.2 --N S --(CH.sub.2).sub.3 --28 i Prop NH.sub.2 i Prop CH.sub.2 --N S --(CH.sub.2).sub.3 --29 CH.sub.3 NH.sub.2 CF.sub.3 CH.sub.2 --N S --(CH.sub.2).sub.7 --30 CH.sub.3 NH.sub.2 CF.sub.3 CH.sub.2 --N S --(CH.sub.2).sub.8 --31 CH.sub.3 NH.sub.2 i Prop CH.sub.2 --N S --(CH.sub.2).sub.932 CH.sub.3 NH.sub.2 CF.sub.3 CH.sub.2 --N S --(CH.sub.2).sub.4 O(CH.sub.2).sub.4 --33 CH.sub.3 NH.sub.2 i Prop CH.sub.2 --N S --(CH.sub.2).sub.4 O(CH.sub.2).sub.4 --34 CH.sub.3 NHCH.sub.3 CF.sub.3 CH.sub.2 --N S --(CH.sub.2).sub.3 --35 CH.sub.3 NH.sub.2 i Prop CH.sub.2 --N S --CH.sub.2 C(CH.sub.3).dbd.CHCH.sub.2 --36 CH.sub.3 NH.sub.2 CF.sub.3 CH.dbd.N S --(CH.sub.2).sub.3 --37 CH.sub.3 NHCH.sub.3 CHF.sub.2 CH.sub.2 --N S --(CH.sub.2).sub.3 --__________________________________________________________________________
TABLE 2__________________________________________________________________________ ##STR27##Example No. R.sup.1 R.sup.2 R.sup.6 D R.sup.8 X-Y A.sub.1 A.sub.2__________________________________________________________________________38 CH.sub.3 NH.sub.2 CF.sub.3 CH H CH.sub.2 --N S --(CH.sub.2).sub.3 --39 CH.sub.3 NH.sub.2 Cl CH CF.sub.3 CH.sub.2 --N S --(CH.sub.2).sub.3 --40 CH.sub.3 NH.sub.2 t But N CF.sub.3 CH.sub.2 --N S --(CH.sub.2).sub.3 --41 CH.sub.3 NH.sub.2 1-Pyrrolyl N CH.sub.3 CH.sub.2 --N S --(CH.sub.2).sub.3 --42 CH.sub.3 NH.sub.2 t But N CF.sub.3 CH.sub.2 --N S --CH.sub.2 C(CH.sub.3).dbd.CHCH.sub.2 --43 CH.sub.3 NH.sub.2 t But N CF.sub.3 CH.sub.2 --N S --(CH.sub.2).sub.3 --44 CH.sub.3 NH.sub.2 t But N t But CH.sub.2 --N S --(CH.sub.2).sub.3 --45 CH.sub.3 NH.sub.2 i Prop C--CN i Prop CH.sub.2 --N S --(CH.sub.2).sub.3 --.__________________________________________________________________________
TABLE 3______________________________________Physical data of the compounds of Examples 16-45Example No. Mp. .degree. C. .sup.1 H-NMR______________________________________16 1.2 (6H); 1.9 (2H); 2.5 (6H); 2.8 (1H); 3.2 (6H); 3.5 (3H); 4.4 (2H); 6.7 (3H); 7.1 (1H)17 194-196.degree. Dihydrochloride18 109-110.degree. Hydrochloride19 132-134.degree.20 1.3 (3H); 2.0 (2H); 2.5 (6H); 3.2 (6H); 3.8 (2H; 4.6 (2H); 7.0 (3H); 7.4 (1H)21 154-155.degree.22 1.0 (3H); 1.8 (2H); 2.0 (2H); 2.5 (6H); 3.1 (6H); 3.7 (2H); 4.4 (2H); 7.0 (3H); 7.3 (1H)23 1.2 (6H); 2.0 (2H): 2.3 (6H); 3.1 (6H); 4.1 (2H); 4.3 (1H); 7.0 (3H); 7.2 (1H)24 1.2 (3H); 1.8 (2H); 2.4 (2H) 2.5 (4H); 2.9 (2H); 3.1 (4H); 3.8 (2H); 6.0 (2H); 6.9 (1H); 7.0 (3H), 7.3 (1H)25 1.0 (3H); 1.7 (2H); 2.0 (2H); 2.5 (2H); 2.6 (4H); 3.0 (6H), 3.7 (2H), 4.6 (2H); 6.6 (1H); 7.0 (3H); 7.4 (1H)26 1.2 (9H); 1.9 (2H); 2.5 (2H); 2.6 (4H); 2.9 (1H); 3.15 (6H); 3.8 (2H); 6.8 (3H); 7.2 (1H)27 0.9 (3H); 1.2 (6H), 1.7 (2H); 1.9 (2H); 2.5 (2H); 2.6 (4H); 2.8 (1H); 2.9 (2H); 3.2 (4H); 3.4 (2H); 6.8 (3H); 7.3 (1H)28 1.2 (6H); 1.5 (6H); 1.9 (2H); 2.4 (2H); 2.5 (4H); 2.8 (1H); 3.2 (6H), 4.3 (3H); 6.75 (3H), 7.15 (1H)29 118-119.degree.30 164-166.degree. Fumarate31 1.2 (6H); 1.4 (14H), 1.7 (2H); 2.4 (2H), 2.6 (4H), 2.8 (1H); 3.0 (2H); 3.2 (4H), 3.4 (3H), 4.6 (2H), 6.8 (3H); 7.2 (1H)32 1.7 (8H); 2.4 (2H); 2.6 (4H); 3.0 (2H; 3.3 (4H); 3.5 (7H); 4.8 (2H); 7.1 (3H); 7.3 (1H)33 1.2 (6H); 1.6 (8H); 2.4 (2H); K 2.6 (4H); 2.9 (1H); 3.1 (2H); 3.2 (4H); 3.3 (7H); 4.8 (2H); 6.8 (3H); 7.2 (1H)34 234-270.degree. Trihydrochloride35 126-129.degree.36 93-100.degree.37 234-235.degree. Dihydrochoride38 153-155.degree.39 116-118.degree.40 51-60.degree.41 65-67.degree.42 67-72.degree.43 121-126.degree.44 180-183.degree. Fumarate45 130-133.degree.______________________________________
TABLE 4__________________________________________________________________________ ##STR28##Example No. R1 R2 R5 R6 R7 R8 R9 X-Y A.sub.1 A.sub.2__________________________________________________________________________46 CH.sub.3 NH.sub.2 H tBut H Me H CH.sub.2 --N S --(CH.sub.2).sub.3 --47 CH.sub.3 NH.sub.2 H tBut H Ph H CH.sub.2 --N S --(CH.sub.2).sub.3 --48 CH.sub.3 NH.sub.2 H tBut H 1-Pyrrolyl H CH.sub.2 --N NH --(CH.sub.2).sub.3 --49 CH.sub.3 NH.sub.2 H iProp H 2-Napht H CH.dbd.C --CH.sub.2 -- --(CH.sub.2).sub.3 --50 CH.sub.3 NH.sub.2 H Et H tBut H CH.sub.2 --N S --(CH.sub.2).sub.3 --51 CH.sub.3 NH.sub.2 OMe tBut H H H CH.dbd.C --CH.sub.2 -- --(CH.sub.2).sub.3 --52 CH.sub.3 NH.sub.2 OMe CF.sub.3 H H H CH.dbd.C S --(CH.sub.2).sub.3 --53 CH.sub.3 NH.sub.2 H CF.sub.3 H tBut H CH.sub.2 --N NH --(CH.sub.2).sub.3 --54 CH.sub.3 NH.sub.2 OiProp iProp H H H CH.sub.2 --N S --(CH.sub.2).sub.3 --55 CH.sub.3 NH.sub.2 H H CN tBut H CH.sub.2 --N O --(CH.sub.2).sub.3 --56 CH.sub.3 NH.sub.2 H H F tBut H CH.dbd.C S --(CH.sub.2).sub.3 --57 CH.sub.3 NH.sub.2 H H Cl iProp H CH.sub.2 --N --CH.sub.2 -- --(CH.sub.2).sub.3 --58 CH.sub.3 NH.sub.2 H tBut H H OMe CH.sub.2 --N S --(CH.sub.2).sub.3 --59 CH.sub.3 NH.sub.2 OMe tBut H tBut H CH.sub.2 --N S --(CH.sub.2).sub.3 --60 CH.sub.3 NH.sub.2 OMe tBut H CF.sub.3 H CH.sub.2 --N S --(CH.sub.2).sub.3 --61 CH.sub.3 NH.sub.2 OMe CF.sub.3 H tBut H CH.sub.2 --N NH --(CH.sub.2).sub.3 --62 CH.sub.3 NH.sub.2 H nProp CN tBut H CH.dbd.C --CH.sub.2 -- --(CH.sub.2).sub.3 --63 CH.sub.3 NH.sub.2 H CF.sub.3 CN iProp H CH.sub.2 --N S --(CH.sub.2).sub.3 --64 CH.sub.3 NH.sub.2 H Ph C.tbd.CH tBut H CH.dbd.C --CH.sub.2 -- --(CH.sub.2).sub.3 --65 CH.sub.3 NH.sub.2 OMe tBut CN H H CH.dbd.C S --(CH.sub.2).sub.3 --66 CH.sub.3 NH.sub.2 H tBut CN CF.sub.3 OMe CH.sub.2 --N NH --(CH.sub.2).sub.3 --67 CH.sub.3 NH.sub.2 OMe nProp F tBut H CH.sub.2 --N S --(CH.sub.2).sub.3 --68 CH.sub.3 NH.sub.2 H Ph CN tBut Me CH.sub.2 --N O --(CH.sub.2).sub.3 --69 CH.sub.3 NH.sub.2 OMe tBut F H H CH.dbd.C S --(CH.sub.2).sub.3 --70 CH.sub.3 NH.sub.2 H iProp H H OMe CH.sub.2 --N S --(CH.sub.2).sub.3 --71 iProp NH.sub.2 H tBut H Me H CH.sub.2 --N S --(CH.sub.2).sub.3 --72 iProp NH.sub.2 H tBut H Ph H CH.sub.2 --N NH --(CH.sub.2).sub.4 --73 iProp NH.sub.2 H tBut H 1-Pyrrolyl H CH.sub.2 --N S --(CH.sub.2).sub.4 --74 iProp NH.sub.2 H iProp H 2-Napht H CH.sub.2 --N --CH.sub.2 -- --(CH.sub.2).sub.3 --75 iProp NH.sub.2 H Et H tBut H CH.sub.2 --N S --(CH.sub.2).sub.5 --76 iProp NH.sub.2 OMe tBut H H H CH.sub.2 --N O --(CH.sub.2).sub.5 --77 iProp NH.sub.2 OMe CF.sub.3 H H H CH.dbd.C NH --(CH.sub.2).sub.4 --78 iProp NH.sub.2 H CF.sub.3 H tBut H CH.sub.2 --N --CH.sub.2 -- --(CH.sub.2).sub.4 --79 iProp NH.sub.2 OiProp iProp H H H CH.dbd.C S --(CH.sub.2).sub.3 --80 iProp NH.sub.2 H H CN tBut H CH.sub.2 --N NH --(CH.sub.2).sub.3 --81 iProp NH.sub.2 H H F tBut H CH.sub.2 --N S --(CH.sub.2).sub.3 --82 iProp NH.sub.2 H H Cl iProp H CH.dbd.C --CH.sub.2 -- --(CH.sub.2).sub.3 --83 iProp NH.sub.2 H tBut H H OMe CH.sub.2 --N S --(CH.sub.2).sub.3 --84 iProp NH.sub.2 OMe tBut H tBut H CH.sub.2 --N S --(CH.sub.2).sub.4 --85 iProp NH.sub.2 OMe tBut H CF.sub.3 H CH.sub.2 --N S --(CH.sub.2).sub.3 --86 iProp NH.sub.2 OMe CF.sub.3 H tBut H CH.sub.2 --N NH --(CH.sub.2).sub.5 --87 iProp NH.sub.2 H nProp CN tBut H CH.dbd.C --CH.sub.2 -- --(CH.sub.2).sub.3 --88 iProp NH.sub.2 H CF.sub.3 CN iProp H CH.sub.2 --N S --(CH.sub.2).sub.4 --89 iProp NH.sub.2 H Ph C.tbd.CH tBut H CH.dbd.C --CH.sub.2 -- --(CH.sub.2).sub.3 --90 iProp NH.sub.2 OMe tBut CN H H CH.dbd.C S --(CH.sub.2).sub.6 --91 iProp NH.sub.2 H tBut CN CF.sub.3 OMe CH.sub.2 --N NH --(CH.sub.2).sub.3 --92 iProp NH.sub.2 OMe nProp F tBut H CH.sub.2 --N S --(CH.sub.2).sub.5 --93 iProp NH.sub.2 H Ph CN tBut Me CH.sub.2 --N O --(CH.sub.2).sub.3 --94 iProp NH.sub.2 OMe tBut F H H CH.dbd.C S --(CH.sub.2).sub.4 --95 iProp NH.sub.2 H iProp H H OMe CH.sub.2 --N S --(CH.sub.2).sub.3 --96 iProp NHMe H tBut H Me H CH.sub.2 --N S --CH.sub.2 --CH.dbd.CH--CH.sub. 2 --97 iProp NHMe H tBut H Ph H CH.sub.2 --N --CH.sub.2 -- --CH.sub.2 --CH.dbd.CH--CH.sub. 2 --98 iProp NHMe H tBut H 1-Pyrrolyl H CH.sub.2 --N S --CH.sub.2 --CH.dbd.CH--CH.sub. 2 --99 iProp NHMe H iProp H 2-Napht H CH.sub.2 --N NH --CH.sub.2 --C(CH.sub.3).dbd.CH --CH.sub.2 --100 iProp NHMe H Et H tBut H CH.sub.2 --N S --CH.sub.2 --C(CH.sub.3).dbd.CH --CH.sub.2 --101 iProp OH OMe tBut H H H CH.sub.2 --N --CH.sub.2 -- --CH.sub.2 --C(CH.sub.3).dbd.CH --CH.sub.2 --102 iProp OH OMe CF.sub.3 H H H CH.sub.2 --N NH --CH.sub.2 --C(CH.sub.3).dbd.CH --CH.sub.2 --103 iProp OH H CF.sub.3 H tBut H CH.sub.2 --N S --CH.sub.2 --CH.dbd.CH--CH.sub. 2 --104 iProp OH OiProp iProp H H H CH.dbd.C --CH.sub.2 -- --CH.sub.2 --CH.dbd.CH--CH.sub. 2 --105 iProp OMe H H CN tBut H CH.dbd.C --CH.sub.2 -- --CH.sub.2 --CH.dbd.CH--CH.sub. 2 --106 iProp OMe H H F tBut H CH.dbd.C S --CH.sub.2 --C(CH.sub.3).dbd.CH --CH.sub.2 --107 iProp OMe H H Cl iProp H CH.dbd.C O --CH.sub.2 --C(CH.sub.3).dbd.CH --CH.sub.2 --108 iProp OMe H tBut H H OMe CH.dbd.C NH --CH.sub.2 --C(CH.sub.3).dbd.CH --CH.sub.2 --109 iProp NHMe OMe tBut H tBut H CH.sub.2 --N S --CH.sub.2 --CH.dbd.CH--CH.sub. 2 --110 iProp NHMe OMe tBut H CF.sub.3 H CH.sub.2 --N --CH.sub.2 -- --CH.sub.2 --CH.dbd.CH--CH.sub. 2 --111 iProp NHMe OMe CF.sub.3 H tBut H CH.sub.2 --N S --CH.sub.2 --CH.dbd.CH--CH.sub. 2 --112 iProp NHMe H nProp CN tBut H CH.sub.2 --N NH --CH.sub.2 --C(CH.sub.3).dbd.CH --CH.sub.2 --113 iProp NHMe H CF.sub.3 CN iProp H CH.sub.2 --N S --CH.sub.2 --C(CH.sub.3).dbd.CH --CH.sub.2 --114 iProp OH H Ph C.tbd.CH tBut H CH.sub.2 --N --CH.sub.2 -- --CH.sub.2 --C(CH.sub.3).dbd.CH --CH.sub.2 --115 iProp OH OMe tBut CN H H CH.sub.2 --N NH --CH.sub.2 --C(CH.sub.3).dbd.CH --CH.sub.2 --116 iProp OH H tBut CN CF.sub.3 OMe CH.sub.2 --N S --CH.sub.2 --CH.dbd.CH--CH.sub. 2 --117 iProp OH OMe nProp F tBut H CH.dbd.C --CH.sub.2 -- --CH.sub.2 --CH.dbd.CH--CH.sub. 2 --118 iProp OMe H Ph CN tBut Me CH.dbd.C --CH.sub.2 -- --CH.sub.2 --CH.dbd.CH--CH.sub. 2 --119 iProp OMe OMe tBut F H H CH.dbd.C S --CH.sub.2 --C(CH.sub.3).dbd.CH --CH.sub.2 --120 iProp OMe H iProp H H OMe CH.dbd.C S --CH.sub.2 --C(CH.sub.3).dbd.CH --CH.sub.2 --__________________________________________________________________________
TABLE 5__________________________________________________________________________ ##STR29##Example No. R1 R2 R6 R8 R9 X-Y A.sub.1 A.sub.2__________________________________________________________________________121 CH.sub.3 NH.sub.2 tBut Ph H CH.sub.2 --N --CH.sub.2 -- --(CH.sub.2).sub.3 --122 CH.sub.3 NH.sub.2 tBut 2-Napht H CH.sub.2 --N S --CH.sub.2 --C(CH.sub.3).dbd.CH--CH.s ub.2 --123 CH.sub.3 NH.sub.2 tBut 1-Pyrrolyl H CH.sub.2 --N S --(CH.sub.2).sub.3 --124 CH.sub.3 NHMe tBut cHex H CH.dbd.C --CH.sub.2 -- --(CH.sub.2).sub.3 --125 CH.sub.3 NH.sub.2 tBut nHex H CH.sub.2 --N S --(CH.sub.2).sub.5 --126 CH.sub.3 NH.sub.2 tBut H OMe CH.sub.2 --N --CH.sub.2 -- --(CH.sub.2).sub.3 --127 CH.sub.3 NHMe iProp H OMe CH.sub.2 --N S --CH.sub.2 --C(CH.sub.3).dbd.CH--CH.s ub.2 --128 CH.sub.3 NH.sub.2 H CH.sub.3 OMe CH.dbd.C NH --(CH.sub.2).sub.3 --129 CH.sub.3 NH.sub.2 H iProp OMe CH.sub.2 --N O --CH.sub.2 --CH.dbd.CH--CH.sub.2 --130 CH.sub.3 NH.sub.2 tBut tBut OMe CH.sub.2 --N --CH.sub.2 -- --(CH.sub.2).sub.3 --131 CH.sub.3 NHMe tBut iProp OMe CH.sub.2 --N S --CH.sub.2 --C(CH.sub.3).dbd.CH--CH.s ub.2 --132 CH.sub.3 NH.sub.2 Ph tBut Cl CH.sub.2 --N S --(CH.sub.2).sub.4 --133 CH.sub.3 NH.sub.2 2-Napht tBut Me CH.dbd.C --CH.sub.2 -- --(CH.sub.2).sub.3 --134 CH.sub.3 NH.sub.2 tBut CF.sub.3 OMe CH.sub.2 --N S --(CH.sub.2).sub.3 --135 CH.sub.3 NH.sub.2 tBut H CH.sub.3 CH.sub.2 --N S --(CH.sub.2).sub.3 --136 iProp NH.sub.2 tBut Ph H CH.sub.2 --N S --(CH.sub.2).sub.3 --137 iProp NH.sub.2 tBut 2-Napht H CH.dbd.C NH --(CH.sub.2).sub.3 --138 iProp NH.sub.2 tBut 1-Pyrrolyl H CH.sub.2 --N O --CH.sub.2 --C(CH.sub.3).dbd.CH--CH.s ub.2 --139 iProp NH.sub.2 tBut cHex H CH.sub.2 --N --CH.sub.2 -- --(CH.sub.2).sub.3 --140 iProp OH tBut nHex H CH.sub.2 --N S --(CH.sub.2).sub.4 --141 nProp OH tBut H OMe CH.dbd.C S --(CH.sub.2).sub.4 --142 nProp OMe iProp H OMe CH.sub.2 --N --CH.sub.2 -- --CH.sub.2 --CH.dbd.CH--CH.sub.2 --143 nProp OMe H CH.sub.3 OMe CH.sub.2 --N --CH.sub.2 -- --(CH.sub.2).sub.3 --144 nProp NCH.sub.2 Ph H iProp OMe CH.sub.2 --N S --CH.sub.2 --C(CH.sub.3).dbd.CH--CH.s ub.2 --145 iProp OH tBut tBut OMe CH.sub.2 --N --CH.sub.2 -- --(CH.sub.2).sub.4 --146 iProp OH tBut iProp OMe CH.sub.2 --N S --CH.sub.2 --CH.dbd.CH--CH.sub.2 --147 iProp OMe Ph tBut Cl CH.sub.2 --N S --(CH.sub.2).sub.5 --148 nProp OMe 2-Napht tBut Me CH.dbd.C --CH.sub.2 -- --(CH.sub.2).sub.3 --149 nProp NCH.sub.2 Ph tBut CF.sub.3 OMe CH.sub.2 --N S --(CH.sub.2).sub.4 --150 nProp NHMe tBut H CH.sub.3 CH.dbd.C S --(CH.sub.2).sub.3 --__________________________________________________________________________
TABLE 6__________________________________________________________________________ ##STR30##Example No. R1 R2 R5 R7 R8 R9 X--Y A1 A2__________________________________________________________________________151 CH.sub.3 NH.sub.2 OMe H tBut H CH.sub.2 --N S --(CH.sub.2).sub.3 --152 CH.sub.3 OH OMe H CF.sub.3 H CH.sub.2 --N S --(CH.sub.2).sub.3 --153 iProp NHMe OMe H tBut H CH.sub.2 --N NH --CH.sub.2 --CH.dbd.CH--CH.sub.2 --154 CH.sub.3 NH.sub.2 H CN tBut H CH.dbd.C --CH.sub.2 -- --CH.sub.2 --C(CH.sub.3).dbd.CH--CH.sub .2 --155 CH.sub.3 NHMe H F tBut H CH.sub.2 --N S --(CH.sub.2).sub.3 --156 cProp NH.sub.2 Me Cl iProp H CH.dbd.C --CH.sub.2 -- --(CH.sub.2).sub.3 --157 CH.sub.3 NHMe H H iProp OMe CH.dbd.C S --(CH.sub.2).sub.3 --158 CH.sub.3 NH.sub.2 H H tBut OMe CH.sub.2 --N NH --CH.sub.2 --CH.dbd.CH--CH.sub.2 --159 iProp NH.sub.2 CN H CF.sub.3 H CH.sub.2 --N S --(CH.sub.2).sub.4 --160 OH NHMe H CN H OMe CH.sub.2 --N O --(CH.sub.2).sub.3 --161 CH.sub.3 OH H H tBu OEt CH.dbd.C S --CH.sub.2 --C(CH.sub.3).dbd.CH--CH.sub .2 --162 Et NH.sub.2 H CN tBut H CH.sub.2 --N --CH.sub.2 -- --(CH.sub.2).sub.3 --163 CH.sub.3 NH.sub.2 Me H iProp H CH.sub.2 --N S --(CH.sub.2).sub.3 --164 iProp NH.sub.2 OMe CN tBut H CH.sub.2 --N S --(CH.sub.2).sub.4 --165 CH.sub.3 NH.sub.2 OMe Me tBut H CH.sub.2 --N S --(CH.sub.2).sub.3 --166 CH.sub.3 NHMe H CN tBut OMe CH.sub.2 --N NH --CH.sub.2 --CH.dbd.CH--CH.sub.2 --167 CH.sub.3 NH.sub.2 Me H tBut OMe CH.dbd.C --CH.sub.2 -- --CH.sub.2 --C(CH.sub.3).dbd.CH--CH.sub .2 --168 iProp NH.sub.2 H Cl CF.sub.3 Me CH.sub.2 --N S --(CH.sub.2).sub.5 --169 OH NHMe OMe CN tBut Me CH.dbd.C --CH.sub.2 -- --(CH.sub.2).sub.3 --170 CH.sub.3 OH Me Me iProp Me CH.dbd.C S --(CH.sub.2).sub.4 --171 CH.sub.3 OH OMe H iProp H CH.sub.2 --N S --(CH.sub.2).sub.3 --__________________________________________________________________________
TABLE 7__________________________________________________________________________ ##STR31##Example No. R1 R2 R5 R6 R8 R9 X--Y A1 A2__________________________________________________________________________172 CH.sub.3 NH.sub.2 H tBut tBut H CH.sub.2 --N S --(CH.sub.2).sub.3 --173 CH.sub.3 OH H tBut Ph H CH.sub.2 --N S --(CH.sub.2).sub.3 --174 iProp NHMe H tBut 1-Pyrrolyl H CH.sub.2 --N NH --CH.sub.2 --CH.dbd.CH--CH.sub.2 --175 CH.sub.3 NH.sub.2 H nPropyl tBut H CH.dbd.C --CH.sub.2 -- --CH.sub.2 --C(CH.sub.3).dbd.CH--CH. sub.2 --176 CH.sub.3 NHMe H CF.sub.3 tBut H CH.sub.2 --N S --(CH.sub.2).sub.3 --177 cProp NH.sub.2 H 2-Napht tBut H CH.dbd.C --CH.sub.2 -- --(CH.sub.2).sub.3 --178 CH.sub.3 NHMe OMe tBut H H CH.dbd.C S --(CH.sub.2).sub.3 --179 CH.sub.3 NH.sub.2 OMe iProp H H CH.sub.2 --N NH --CH.sub.2 --CH.dbd.CH--CH.sub.2 --180 iProp NH.sub.2 OMe H CF.sub.3 H CH.sub.2 --N S --(CH.sub.2).sub.4 --181 OH NHMe H tBut H OMe CH.sub.2 --N O --(CH.sub.2).sub.3 --182 CH.sub.3 OH H iProp H Me CH.dbd.C S --CH.sub.2 --C(CH.sub.3).dbd.CH--CH. sub.2 --183 Et NH.sub.2 CN tBut H H CH.sub.2 --N --CH.sub.2 -- --(CH.sub.2).sub.3 --184 CH.sub.3 NH.sub.2 H H CF.sub.3 Me CH.sub.2 --N S --(CH.sub.2).sub.3 --185 OH NHMe OMe tBut iProp H CH.sub.2 --N S --(CH.sub.2).sub.4 --186 CH.sub.3 OH OMe CF.sub.3 tBut H CH.sub.2 --N NH --CH.sub.2 --CH.dbd.CH--CH.sub.2 --187 Et NH.sub.2 Me tBut nProp H CH.dbd.C --CH.sub.2 -- --CH.sub.2 --C(CH.sub.3).dbd.CH--CH. sub.2 --188 CH.sub.3 NH.sub.2 Me tBut H OMe CH.sub.2 --N S --(CH.sub.2).sub.5 --189 CH.sub.3 NH.sub.2 OMe tBut tBut OMe CH.dbd.C --CH.sub.2 -- --(CH.sub.2).sub.3 --190 iProp NH.sub.2 Me CF.sub.3 tBut OMe CH.dbd.C S --(CH.sub.2).sub.4 --191 CH.sub.3 OH H nProp tBut H CH.sub.2 --N S --(CH.sub.2).sub.3 --__________________________________________________________________________
TABLE 8__________________________________________________________________________ ##STR32##Example No. R1 R2 R6 R7 R8 R9 X--Y A1 A2__________________________________________________________________________192 CH.sub.3 NH.sub.2 tBut H tBut H CH.sub.2 --N S --(CH.sub.2).sub.3 --193 CH.sub.3 OH tBut CN H H CH.sub.2 --N S --(CH.sub.2).sub.3 --194 iProp NHMe tBut H H OMe CH.sub.2 --N NH --CH.sub.2 --CH.dbd.CH--CH.sub.2 --195 CH.sub.3 NH.sub.2 H CN tBu H CH.dbd.C --CH.sub.2 -- --CH.sub.2 --C(CH.sub.3).dbd.CH--CH.su b.2 --196 CH.sub.3 NHMe CF.sub.3 H tBut H CH.sub.2 --N S --(CH.sub.2).sub.3 --197 cProp NH.sub.2 nProp H iProp H CH.dbd.C --CH.sub.2 -- --(CH.sub.2).sub.3 --198 CH.sub.3 NHMe H H iProp OMe CH.dbd.C S --(CH.sub.2).sub.3 --199 CH.sub.3 NH.sub.2 tBut H tBut H CH.sub.2 --N NH --CH.sub.2 --CH.dbd.CH--CH.sub.2 --200 iProp NH.sub.2 tBut CN H H CH.sub.2 --N S --(CH.sub.2).sub.4 --201 OH NHMe tBut H H OMe CH.sub.2 --N O --(CH.sub.2).sub.3 --202 CH.sub.3 OH H CN tBu H CH.dbd.C S --CH.sub.2 --C(CH.sub.3).dbd.CH--CH.su b.2 --203 Et NH.sub.2 CF.sub.3 H tBut H CH.sub.2 --N --CH.sub.2 -- --(CH.sub.2).sub.3 --204 CH.sub.3 NH.sub.2 nProp H iProp H CH.sub.2 --N S --(CH.sub.2).sub.3 --205 CH.sub.3 NH.sub.2 nProp CN tBut H CH.sub.2 --N S --(CH.sub.2).sub.4 --206 CH.sub.3 OH CF.sub.3 CN iProp H CH.sub.2 --N S --(CH.sub.2).sub.3 --207 iProp NHMe Ph C.dbd.CH tBut H CH.sub.2 --N NH --CH.sub.2 --CH.dbd.CH--CH.sub.2 --208 CH.sub.3 NH.sub.2 tBut CN tBut H CH.dbd.C --CH.sub.2 -- --CH.sub.2 --C(CH.sub.3).dbd.CH--CH.su b.2 --209 CH.sub.3 NHMe tBut H nProp OMe CH.sub.2 --N S --(CH.sub.2).sub.3 --210 cProp NH.sub.2 Ph H tBut OMe CH.dbd.C --CH.sub.2 -- --(CH.sub.2).sub.5 --211 CH.sub.3 NHMe CF.sub.3 H tBut OMe CH.dbd.C S --(CH.sub.2).sub.3 --212 CH.sub.3 NH.sub.2 tBut F H Me CH.sub.2 --N NH --CH.sub.2 --CH.dbd.CH--CH.sub.2 --213 iProp NH.sub.2 nProp CN tBut Me CH.sub.2 --N S --CH.sub.2 --CH.dbd.CH--CH.sub.2 --214 CH.sub.3 OH nProp C.dbd.CH tBut OMe CH.dbd.C --CH.sub.2 -- --CH.sub.2 --C(CH.sub.3).dbd.CH--CH.su b.2 --215 iProp NHMe tBut CN H OMe CH.sub.2 --N S --(CH.sub.2).sub.4 --216 CH.sub.3 OH H H iProp OMe CH.sub.2 --N S --(CH.sub.2).sub.3 --__________________________________________________________________________
Examples of Pharmaceutical Forms
______________________________________Tablets of the following composition are compressedin a tabletting machine in a conventional manner:______________________________________A) Tablets40 mg of substance of Example 1120 mg of corn starch13.5 mg of gelatin45 mg of lactose2.25 mg of Aerosil .RTM. (chemically pure silica in sub- microscopically fine dispersion)6.75 mg of potato starch (as 6% strength paste)B) Sugar-coated tablets20 mg of substance of Example 460 mg of core composition70 mg of sugar-coating composition______________________________________
The core composition comprises 9 parts of corn starch, 3 parts of lactose and 1 part of vinylpyrrolidone/vinyl acetate 60:40 copolymer. The sugar-coating composition comprises 5 parts of sucrose, parts of corn starch, 2 parts of calcium carbonate and 1 part of talc. The sugar-coated tablets produced in this way are subsequently provided with an enteric coating.
Biological Investigations--Receptor-Binding Studies
1) D.sub.3 binding assay
Cloned human D.sub.3 receptor-expressing CCL 1.3 mouse fibroblasts obtained from Res. Biochemicals Internat. One Strathmore Rd., Natick, Mass. 01760-2418 USA, were used for the binding studies.
Cell Preparation
The D.sub.3 -expressing cells were grown in RPMI-1640 containing 10% fetal calf serum (GIBCO No. 041-32400 N); 100 U/ml penicillin and 0.2% Streptomycin (GIBCO BRL, Gaithersburg, Md., USA). After 48 h, the cells were washed with PBS and incubated with 0.05% trypsin-containing PBS for 5 min. Neutralization with medium was then carried out, and the cells were collected by centrifugation at 300.times.g. To lyze the cells, the pellet was briefly washed with lysis buffer (5 mM tris-HCl, pH 7.4, with 10% glycerol) and then incubated in a concentration of 10.sup.7 cells/ml of lysis buffer at 4.degree. C. for 30 min. The cells were centrifuged at 200.times.g for 10 min and the pellet was stored in liquid nitrogen.
Binding Assays
For the D.sub.3 receptor-binding assay, the membranes were suspended in incubation buffer (50 mM tris-HCl, pH 7.4, with 120 mM NaCl, 5 mM KCl, 2 mM CaCl.sub.2, 2 mM MgCl.sub.2, 10 .mu.M quinolinol, 0.1% ascorbic acid and 0.1% BSA) in a concentration of about 10.sup.6 cells/250 .mu.l of assay mixture and incubated at 30.degree. C. with 0.1 nM .sup.125 iodosulpiride in the presence and absence of test substance. The non-specific binding was determined using 10.sup.-6 M spiperone.
After 60 min, the free and the bound radioligand was separated by filtration through GF/B glass fiber filters (Whatman, England) on a Skatron cell collector (Skatron, Lier, Norway), and the filters were washed with ice-cold tris-HCl buffer, pH 7.4. The radioactivity collected on the filters was quantified using a Packard 2200 CA liquid scintillation counter.
The K.sub.i values were determined by non-linear regression analysis using the LIGAND program.
2) D.sub.2 Binding Assay
Membrane Preparation
a) Nucleus Caudatus (Bovine)
Nucleus caudatus was removed from bovine brain and washed with ice-cold 0.32 M sucrose solution. After determination of the weight, the material was comminuted and homogenized in 5-10 volumes of sucrose solution using a Potter-Evehjem homogenizer (500 rpm). The homogenate was centrifuged at 3,000.times.g for 15 minutes (4.degree. C.), and the resulting supernatant was subjected to another 15-minute centrifugation at 40,000.times.g. The residue was then washed twice, by resuspension and centrifugation, with 50 mM tris-HCl, pH 7.4. The membranes were stored in liquid nitrogen until used.
b) Striatum (Rat)
Striati from Sprague-Dawley rats were washed in ice-cold 0.32 M sucrose solution. After determination of the weight, the parts of the brain were homogenized in 5-10 volumes of sucrose solution using a Potter-Elvehjem homogenizer (500 rpm). The homogenate was centrifuged at 40,000.times.g for 10 minutes (4.degree. C.), and then the residue was washed several times, by resuspension and centrifugation, with 50 mM tris-HCl, 0.1 mM EDTA and 0.01% ascorbic acid (pH 7.4). The washed residue was resuspended in the abovementioned buffer and incubated at 37.degree. C. for 20 minutes (to break down the endogenous dopamine). The membranes were then washed twice with buffer and portions were frozen in liquid nitrogen. The membrane preparation was stable for a maximum of one week.
Binding Assay
a) .sup.3 H-Spiperone (D.sub.2low)
Nucleus caudatus membranes were taken up in incubation buffer (mM: tris-HCl 50, NaCl 120, KCl 5, MgCl.sub.2 1, CaCl.sub.2 2, pH 7.4). Various mixtures, each of 1 ml, were prepared:
Total binding: 400 .mu.g of membranes+0.2 nmol/1 .sup.3 H-spiperone (Du Pont de Nemours, NET-565).
Non-specific binding: as mixtures for total binding+10 .mu.M (+)-butaclamol.
Test substance: as mixtures for total binding+increasing concentrations of test substance.
After incubation at 25.degree. C. for 60 minutes, the mixtures were filtered through GF/B glass fibre filters (Whatman, England) on a Skatron cell collector (from Zinsser, Frankfurt), and the filters were washed with ice-cold 50 mM tris-HCl buffer, pH 7.4. The radioactivity collected on the filters was quantified using a Packard 2200 CA liquid scintillation counter.
The K.sub.i values were determined by non-linear regression analysis using the LIGAND program or by conversion of the IC.sub.50 values using the formula of Cheng and Prusoff.
b) .sup.3 H-ADTN (D.sub.2high)
Striatum membranes were taken up in incubation buffer (50 nM tris-HCl, pH 7.4, 1 mM MnCl.sub.2 and 0.1% ascorbic acid).
Various mixtures, each of 1 ml, were prepared.
Total binding: 300 .mu.g wet weight+1 nM .sup.3 H-ADTN (Du Pont de Nemours, customer synthesis)+100 nM SCH 23390 (occupation of D1 receptors).
Non-specific binding: as mixtures for total binding+50 nM spiperone.
Test substance: as mixtures for total binding+increasing concentrations of test substance.
After incubation at 25.degree. C. for 60 minutes, the mixtures were filtered through GF/B glass fibre filters (Whatman, England) on a Skatron cell collector (from Zinsser, Frankfurt), and the filters were washed with ice-cold 50 mM tris-HCl buffer, pH 7.4. The radioactivity collected on the filters was quantified using a Packard 2200 CA liquid scintillation counter.
The evaluation took place as under a).
In these assays, the compounds according to the invention show very good affinities and high selectivities for the D.sub.3 receptor. The results obtained for representative compounds are compiled in the following Table 9.
TABLE 9______________________________________Receptor binding D.sub.3 D.sub.2Example .sup.125 I-sulpiride .sup.3 H-spiperone SelectivityNo. K.sub.i [nM] K.sub.i [mM] K.sub.i D.sub.2 /K.sub.i D.sub.3______________________________________10 4.5 219 4915 8.8 517 5824 1.8 120 6741 8.1 1,500 18542 13.4 2,450 18237 1.7 300 176______________________________________
For comparison, the compound of the formula ##STR33## (U.S. Pat. No. 4,577,020; Example 3) was subjected to the above D.sub.3 binding assay. A K.sub.i of 4100 [nM] was found; ie. the compound has virtually no affinity for the D.sub.3 receptor.

Number	Name	Date
4338453	Gall	Jul 1982
4408049	Gall	Oct 1983
4487773	Temple, Jr.	Dec 1984
4575555	Temple, Jr.	Mar 1986
4577020	Gall	Mar 1986
4613600	Gammans	Sep 1986
4711885	Wierzbicki	Dec 1987
4886805	Bru-Magniez	Dec 1989
5292739	Merce-Vidal et al.	Mar 1994
5346896	Ward et al.	Sep 1994

Number	Date	Country
568 437	Nov 1993	EPX
1053085	Dec 1966	GBX

Triazole compounds and the use thereof

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

US Classifications

Field of Search

US

International Classifications

Abstract

Description

Claims

Priority Claims (1)

PCT Information

US Referenced Citations (10)

Foreign Referenced Citations (2)

Non-Patent Literature Citations (3)

Entry
Sokoloff et al., Nature, vol. 347, Sep. 1990, pp. 146-151.
Reitz et al., J. Med. Chem., 37, 1994, pp. 1060-1062.
Cram & Hammond, "Organic Chemistry," McGraw-Hill Book Co., NY 2nd Ed, pp. 565-567, 1964.